Loading
Latest filing published 04 Aug 2025 for Nuo Therapeutics, Inc., €64k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Peter Clausen, listed as senior executive, appears in our data through filings on Nuo Therapeutics, Inc. shares, published by SEC (Form 4). Over a trading history stretching from 5 May 2016 to 31 July 2025, the count stands at 7 filings.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The newest entry dates from 4 August 2025: an option exercise of €64k, in Nuo Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 3 days. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
5 of 5 declarations